As the world becomes aware of Hyderabad’s position as the “Vaccine Capital of the World,” Biological E has announced vaccine manufacturing expansion plans worth more than Rs 1,800 crore.
More than 2,500 people in Genome Valley will gain employment as a result of this.
The expansion is primarily intended to increase vaccine manufacturing, as well as generic injectables and R&D.
Industries and IT Minister KT Rama Rao made the announcement following a meeting with Biological E Managing Director Mahima Datla.
Jayesh Ranjan, Principal Secretary for Industries, and Shakthi M Nagappan, Director of Telangana Lifesciences, were also present.
“I am delighted to announce the expansion plans of Biological E in Genome Valley,” Rao said.
Additionally, Biological E’s Managing Director, Datla, stated, “I am thankful to the government of Telangana and Chief Minister K Chandrashekar Rao for facilitating our ability to expand even during the pandemic.”
ALSO READ: Another landmark cable bridge to come up in Hyderabad
With a capacity of approximately 9 billion doses per year, Hyderabad city accounts for one-third of global vaccine production. Biological E’s investment will increase capacity by 5 billion doses per year, bringing the total capacity to approximately 14 billion doses per year.
The investment will go toward the production of Janssen Covid vaccines, MR vaccines, PCV vaccines, Typhoid vaccines, Covid vaccines, Tetanus Toxide Ampoules, IPV vaccines, and Pertussis vaccines, as well as biological APIs and formulations along with specialty Generic Injectables and R&D with employment potential of 2,518 people.
ALSO READ: Hyderabad to house GHASL and Schneider manufacturing unit
All of these activities will take place in Genome Valley, India’s first organized cluster for Life Sciences R&D and Clean Manufacturing activities, which will be equipped with world-class infrastructure in the form of industrial/knowledge parks, special economic zones (SEZs), multi-tenanted dry and wet laboratories, and incubation facilities.
It is home to over 200 companies with a scientific workforce of approximately 15,000 professionals, including marquee global names such as Novartis, GlaxoSmithKline, Ferring Pharma, Chemo, DuPont, Ashland, United States Pharmacopeia, and Lonza, among many others.
(This story has been sourced from a third-party syndicated feed, agencies. Raavi Media accepts no responsibility or liability for the text’s dependability, trustworthiness, reliability, and data. Raavi Media management/ythisnews.com reserves the sole right to alter, delete or remove (without notice) the content at its absolute discretion for any reason whatsoever.)
